Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.69 | 3.48 | 0.52 | -1.87 |
| FCF Yield | -0.76% | 3.13% | 5.31% | 4.26% |
| EV / EBITDA | 207.43 | 20.69 | 14.51 | 17.40 |
| Quality | ||||
| ROIC | 2.62% | 16.44% | 21.81% | 20.99% |
| Gross Margin | 86.11% | 87.21% | 87.90% | 88.06% |
| Cash Conversion Ratio | 0.92 | 0.98 | 1.24 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.26% | 9.22% | 12.90% | 22.08% |
| Free Cash Flow Growth | -124.10% | -16.47% | 62.97% | -19.55% |
| Safety | ||||
| Net Debt / EBITDA | -5.80 | -2.08 | -2.17 | -2.00 |
| Interest Coverage | -7.61 | 86.89 | 78.60 | 45.24 |
| Efficiency | ||||
| Inventory Turnover | 1.27 | 1.71 | 2.35 | 2.56 |
| Cash Conversion Cycle | 242.28 | 165.94 | 111.89 | 118.60 |